- Home
- HCTI vs PCSA Comparison
HCTI vs PCSA Comparison
Compare HCTI & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCTI
- PCSA
- Stock Information
- Founded
- HCTI 2020
- PCSA 2011
- Country
- HCTI United States
- PCSA United States
- Employees
- HCTI N/A
- PCSA N/A
- Industry
- HCTI Retail: Computer Software & Peripheral Equipment
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- HCTI Technology
- PCSA Health Care
- Exchange
- HCTI Nasdaq
- PCSA Nasdaq
- Market Cap
- HCTI 13.5M
- PCSA 12.0M
- IPO Year
- HCTI 2021
- PCSA N/A
- Fundamental
- Price
- HCTI $2.78
- PCSA $0.41
- Analyst Decision
- HCTI
- PCSA Strong Buy
- Analyst Count
- HCTI 0
- PCSA 1
- Target Price
- HCTI N/A
- PCSA $1.00
- AVG Volume (30 Days)
- HCTI 2.4M
- PCSA 24.0M
- Earning Date
- HCTI 11-13-2025
- PCSA 11-06-2025
- Dividend Yield
- HCTI N/A
- PCSA N/A
- EPS Growth
- HCTI N/A
- PCSA N/A
- EPS
- HCTI N/A
- PCSA N/A
- Revenue
- HCTI $11,866,000.00
- PCSA N/A
- Revenue This Year
- HCTI N/A
- PCSA N/A
- Revenue Next Year
- HCTI N/A
- PCSA N/A
- P/E Ratio
- HCTI N/A
- PCSA N/A
- Revenue Growth
- HCTI N/A
- PCSA N/A
- 52 Week Low
- HCTI $1.37
- PCSA $0.15
- 52 Week High
- HCTI $473.10
- PCSA $1.50
- Technical
- Relative Strength Index (RSI)
- HCTI 50.93
- PCSA 65.09
- Support Level
- HCTI $2.50
- PCSA $0.37
- Resistance Level
- HCTI $3.00
- PCSA $0.44
- Average True Range (ATR)
- HCTI 0.40
- PCSA 0.06
- MACD
- HCTI 0.02
- PCSA 0.02
- Stochastic Oscillator
- HCTI 40.99
- PCSA 61.18
About HCTI Healthcare Triangle Inc.
Healthcare Triangle Inc is a healthcare information technology company focused on advancing industry-transforming solutions in the sectors of cloud services, data science, and professional and managed services for the healthcare and life sciences industry. The company reinforces healthcare progress through technology and extensive industry know-how. HTI supports healthcare providers and payors, hospitals, and Pharma Life Sciences organizations in their effort to improve health outcomes by enabling the adoption of new technologies, data enlightenment, business agility, and accelerated response to immediate business needs and competitive threats. It provides services under three operating segments: Software Services, Managed Services, and Support and Platform Services.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).